Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial

Ritonavir-boosted tipranavir (TPV/r) was evaluated as initial therapy in treatment-naïve HIV-1-infected patients because of its potency, unique resistance profile, and high genetic barrier. Trial 1182.33, an open-label, randomized trial, compared two TPV/r dose combinations versus ritonavir-boosted...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, David A., Cordery, Damien V., Zajdenverg, Roberto, Ruxrungtham, Kiat, Arastéh, Keikawus, Bergmann, Frank, Neto, José L. de Andrade, Scherer, Joseph, Chaves, Ricardo L., Robinson, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701182/
https://www.ncbi.nlm.nih.gov/pubmed/26730818
http://dx.doi.org/10.1371/journal.pone.0144917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701182/
https://www.ncbi.nlm.nih.gov/pubmed/26730818
http://dx.doi.org/10.1371/journal.pone.0144917

Ejemplares similares